

# An investigative study into the recovery index, attentiveness and state of memory after xenon or isoflurane anaesthesia

<b>Submission date</b> 30/12/2009	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 16/03/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 25/05/2010	<b>Condition category</b> Surgery	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Ralph Stuttmann

### Contact details

Mersburgerstraße 165

Halle ( Saale)

Germany

06112

ralph.stuttmann@bergmannstrost.com

## Additional identifiers

### Protocol serial number

23/2002

## Study information

### Scientific Title

A single centre randomised controlled investigative study into the recovery index, attentiveness and state of memory after xenon or isoflurane anaesthesia

**Study objectives**

The aim of the study was to evaluate the efficacy of two balanced anaesthetic regimens with respect to recovery of early post-operative cognitive function at the day of operation (assessed as attentiveness and memory; this was the primary criterion) and emergence profile (assessed as the recovery index; this was the secondary criterion). The hypothesis was primarily that patients have a significantly higher status of attentiveness and memory 1 and 3 hours after inhalation anaesthesia with xenon compared to isoflurane anaesthesia, and that patients reach their pre-operative level of cognitive function within 3 hours after extubation. The second hypotheses was that the time to wake up from the anaesthetic was predicted to be shorter following xenon than following isoflurane.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Ethics Committee of the University Witten/Herdecke approved on the 11th September 2002 (ref: 23/2002). Patient insurance by Winterthur International (ref: DE 00020283-LI-02A-715).

**Study design**

Single centre single blind randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Post-operative cognitive function

**Interventions**

ASA I and II patients undergoing both long and short surgical interventions were randomised to receive either general anaesthesia with xenon or general anaesthesia with isoflurane. The inhalational anaesthesia was carried out following standard procedures using appropriate equipment.

Patients were randomised in blocks of 4 - 8 patients in order to balance the groups. The varying size of blocks was to counteract the differing frequencies of the operations and also any influence of duration and invasiveness of the operations. A total of 61 patients who met the pre-defined inclusion and exclusion criteria were randomised either to receive xenon in oxygen (Xenon group, n = 31) or isoflurane in stickoxydal (Isoflurane group, n = 30).

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Xenon, isoflurane

**Primary outcome(s)**

Syndrome Short Test

**Key secondary outcome(s))**

1. Recovery Index
2. Aldrete Score

**Completion date**

31/05/2005

**Eligibility****Key inclusion criteria**

1. Healthy American Society of Anaesthesiologists (ASA) grade I and II patients
2. Aged over 18 years of age, either sex
3. Scheduled for four different types of elective surgery. The types of surgery were:
  - 3.1. Visceral surgical strumectomy
  - 3.2. Augmentation or reduction mammoplasty
  - 3.3. Liposuction in obese patients
  - 3.4. Knee arthroscopy

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Patients with ASA classification grade greater than 2
2. Aged less than 18 years
3. Emergency surgery
4. Alcohol or drug abuse
5. Organ dysfunction of liver, kidney or pulmonary system
6. Diabetes

**Date of first enrolment**

01/06/2003

**Date of final enrolment**

31/05/2005

# Locations

## Countries of recruitment

Germany

## Study participating centre

Mersburgerstraße 165

Halle ( Saale)

Germany

06112

# Sponsor information

## Organisation

BG-Kliniken Bergmannstrost (Germany)

## ROR

<https://ror.org/042g9vq32>

# Funder(s)

## Funder type

Industry

## Funder Name

Messer Griesheim/AIR LIQUIDE Medical GmbH (Germany)

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	07/05/2010		Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes

